The Scientist reports that the FDA is changing its conflict-of-interest policy. In the past, if they wanted an interest waiver, the members of the organization's 32 advisory panels and committees would simply have to tell the FDA if they had any connections with a company that had a drug or medical device under FDA review, or with one of its competitors. Now, The Scientist says, committee members must be prepared to publicly disclose the names of the companies they're connected to and how much money is involved, if they want a waiver from the FDA. The FDA isn't asking for specific dollar amounts, however, but "magnitudes" of financial involvement in $5,000 increments.
Public Disclosure of FDA Panel Members' Conflicts of Interest
Apr 23, 2010